Spinraza Archives -

Market Access/ News/ News/ News/ Sales and Marketing

Roche puts pressure on SMA rivals with new FDA approval

Phil Taylor Biogen, Evrysdi, Novartis, PTC Therapeutics, regulatory approval, Roche, SMA, Spinraza, Zolgensma 0 Comment

Roche and PTC Therapeutics’ Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger

Roche puts pressure on SMA rivals with new FDA approval

https://pharmaphorum.com/news/roche-puts-pressure-on-sma-rivals-with-new-fda-approval/

News/ News/ R&D

Biogen looks beyond Spinraza in SMA with Ionis deal

Phil Taylor Biogen, Evrysdi, Ionis Pharmaceuticals, Novartis, rare disease, Roche, spinal muscular atrophy, Spinraza, Zolgensma 0 Comment

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with

Biogen looks beyond Spinraza in SMA with Ionis deal

https://pharmaphorum.com/news/biogen-looks-beyond-spinraza-in-sma-with-ionis-deal/

News/ News/ R&D

Roche builds evidence for Evrysdi’s benefits in younger SMA patients

Phil Taylor Biogen, Evrysdi, Novartis, Roche, spinal muscular atrophy, Spinraza, Zolgensma 0 Comment

Roche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing

Roche builds evidence for Evrysdi’s benefits in younger SMA patients

https://pharmaphorum.com/news/roche-builds-evidence-for-evrysdis-benefits-younger-sma-patients/

News/ News/ R&D

Biogen plans trial of Spinraza in patients not responding to SMA gene therapy

Richard Staines Biogen, gene therapy, Novartis, Rare diseases, SMA, Spinraza, Zolgensma 0 Comment

Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded

Biogen plans trial of Spinraza in patients not responding to SMA gene therapy

https://pharmaphorum.com/news/biogen-trialling-spinraza-in-patients-not-responding-to-novartis-sma-gene-therapy/

Market Access/ News/ News

FDA cues up May verdict for Roche’s SMA challenger risdiplam

Phil Taylor Biogen, Novartis, Risdiplam, Roche, spinal muscular atrophy, Spinraza, Zolgensma 0 Comment

The FDA has started a priority review of Roche’s spinal muscular atrophy (SMA) candidate risdiplam, with a decision

FDA cues up May verdict for Roche’s SMA challenger risdiplam

https://pharmaphorum.com/news/fda-cues-up-may-verdict-for-roches-sma-challenger-risdiplam/

Market Access/ News/ News

NHS chief hails SMA drug deal – and was that a swipe at Vertex?

Richard Staines Biogen, market access, NICE, Rare diseases, Spinraza 0 Comment

Children in England with the rare muscle wasting disease spinal muscular atrophy (SMA) will get access to Biogen’s

NHS chief hails SMA drug deal – and was that a swipe at Vertex?

https://pharmaphorum.com/news/nhs-chief-hails-sma-drug-deal-and-was-that-a-swipe-at-vertex/

Several Prescription Pill Bottles in a Pile

News/ News/ R&D

PTC shares soar after SMA drug data impresses market

Piotr Wnuk AveXis, Biogen, Novartis, PTC Therapeutics, SMA, spinal muscular atrophy, Spinraza 0 Comment

After failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on

PTC shares soar after SMA drug data impresses market

https://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/

Market Access/ News/ News/ Pharma Market Access

Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chances

Andrew McConaghie Alzheimer's disease, Biogen, Spinraza 0 Comment

Biogen has given investors a pleasant surprise with better-than-expected profits in Q3, but has puzzled analysts with a

Biogen sees Spinraza slow down in Q3, bullish on Alzheimer’s chances

https://pharmaphorum.com/news/biogen-sees-spinraza-slow-q3/

Trending

Spinraza

Login